Professor | Mingqian Feng | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Mingqian Feng
Contact Information	fengmingqian@mail.hzau.edu.cn
Language ability	Chinese, English
Province	Hubei

Upload Avatar (500 x 500)

Name

Mingqian Feng

Contact Information

fengmingqian@mail.hzau.edu.cn

Language ability

Chinese, English

Province

Hubei

University/Lab Affiliation and Title	Huazhong Agricultural University
Faculty	Life Sciences
Academic Background & Achievements	1993.9-1997.7 Bachelor: Northwest A&F University, Plant Genetics and Breeding 1997.9-2000.7 Master: Northwest A&F University, Biochemistry and Molecular Biology 2005.9-2008.7 PhD: Nanjing University, Biology
Work Experience	2000.7-2005.9 - Huazhong Agricultural University - Lecturer 2008.10-2013.11 - NIH, USA - Postdoctoral Researcher 2013.11-2015.12 - NIH, USA - Assistant Researcher 2015.12-present - Huazhong Agricultural University - Professor

University/Lab Affiliation and Title

Huazhong Agricultural University

Faculty

Life Sciences

Academic Background & Achievements

1993.9-1997.7 Bachelor: Northwest A&F University, Plant Genetics and Breeding
1997.9-2000.7 Master: Northwest A&F University, Biochemistry and Molecular Biology
2005.9-2008.7 PhD: Nanjing University, Biology

Work Experience

2000.7-2005.9 - Huazhong Agricultural University - Lecturer
2008.10-2013.11 - NIH, USA - Postdoctoral Researcher
2013.11-2015.12 - NIH, USA - Assistant Researcher
2015.12-present - Huazhong Agricultural University - Professor

Areas of Focus	Antibody engineering and tumor immunotherapy Immunotherapy for hematological diseases Acute liver failure and bioartificial liver therapy
Publications	A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding., Dianbao Zuo, Yuankui Zhu, Ke Wang, Youjia Qin, Yiyi Su, Sina Lan, Yunyi Li, Shuang Dong, Yinming Liang, Mingqian Feng, 2024 Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects., Yuankui Zhu, Ke Wang, Linghe Yue, Dianbao Zuo, Junfeng Sheng, Sina Lan, Zilong Zhao, Shuang Dong, Sheng Hu, Chen Xin, Mingqian Feng, 2024 Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody., Huixia He, Feifei Lei, Le Huang, Ke Wang, Yaxi Yang, Liu Chen, Yun Peng, Yinming Liang, Huabing Tan, Xiaoyan Wu, Mingqian Feng, 2023 EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma., Le Huang, Huixia He, Ke Wang, Xuqian Ma, Xin Chen, Wenxin Chen, Xuan Wang, Xiaobing Jiang, Mingqian Feng, 2022 Highly potent immunotoxins targeting the N-lobe of GPC3 for immunotherapy of hepatocellular carcinoma., Jingwen Li, Lanxin Xiang, Qian Wang, Xuqian Ma, Xin Chen, Yuankui Zhu, Yaxi Yang, Le Huang, Huixia He, Lilei Xu, Xinjun Liang, Shuang Dong, Sheng Hu, Hanjie Li, Mingqian Feng, 2022 Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and Irinotecan is potent in suppressing tumor growth in mice., Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho, Mingqian Feng, 2022 Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth., Xin Chen, Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng, 2020 Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma., Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M, 2013

Areas of Focus

Antibody engineering and tumor immunotherapy
Immunotherapy for hematological diseases
Acute liver failure and bioartificial liver therapy

Publications

A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding., Dianbao Zuo, Yuankui Zhu, Ke Wang, Youjia Qin, Yiyi Su, Sina Lan, Yunyi Li, Shuang Dong, Yinming Liang, Mingqian Feng, 2024
Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects., Yuankui Zhu, Ke Wang, Linghe Yue, Dianbao Zuo, Junfeng Sheng, Sina Lan, Zilong Zhao, Shuang Dong, Sheng Hu, Chen Xin, Mingqian Feng, 2024
Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody., Huixia He, Feifei Lei, Le Huang, Ke Wang, Yaxi Yang, Liu Chen, Yun Peng, Yinming Liang, Huabing Tan, Xiaoyan Wu, Mingqian Feng, 2023
EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma., Le Huang, Huixia He, Ke Wang, Xuqian Ma, Xin Chen, Wenxin Chen, Xuan Wang, Xiaobing Jiang, Mingqian Feng, 2022
Highly potent immunotoxins targeting the N-lobe of GPC3 for immunotherapy of hepatocellular carcinoma., Jingwen Li, Lanxin Xiang, Qian Wang, Xuqian Ma, Xin Chen, Yuankui Zhu, Yaxi Yang, Le Huang, Huixia He, Lilei Xu, Xinjun Liang, Shuang Dong, Sheng Hu, Hanjie Li, Mingqian Feng, 2022
Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and Irinotecan is potent in suppressing tumor growth in mice., Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho, Mingqian Feng, 2022
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth., Xin Chen, Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng, 2020
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma., Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M, 2013

Antibody Engineering Tumor Immunotherapy Hematological Diseases Acute Liver Failure Bioartificial

Yinghui Zhu - Tongji University

Feng Wang - University of Chinese Academy of Sciences

Lijian Hui - University of Chinese Academy of Sciences

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us